Bank of America just raised its EUR/USD forecast
William Guyer, the Chief Development Officer at Corcept Therapeutics Inc (NASDAQ:CORT), recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission. On May 6, 2025, Guyer sold 7,060 shares of common stock at an average price of $74.31 per share, amounting to a total transaction value of approximately $524,652. This sale was conducted under a pre-established 10b5-1 trading plan, adopted on November 27, 2024. The transaction comes as Corcept, currently valued at $7.55 billion, has delivered an impressive 168% return over the past year, according to InvestingPro data.
In addition to the sale, Guyer also exercised stock options to acquire 7,060 shares at $21.65 per share, with the total value of the transaction being $152,849. Following these transactions, Guyer holds 5,487 shares of Corcept Therapeutics common stock directly. The company maintains strong financial health with a "GREAT" rating from InvestingPro, supported by 30.93% revenue growth and robust liquidity metrics. For detailed valuation analysis and 13 additional ProTips, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Corcept Therapeutics reported first-quarter earnings per share of $0.17, surpassing analyst expectations of $0.14, while revenue for the quarter was $157.2 million, falling short of the anticipated $177.9 million. Despite this revenue miss, Corcept maintains its 2025 sales guidance for Korlym, projecting sales between $900 million and $950 million. This forecast indicates significant growth, supported by a notable increase in Korlym prescriptions. Piper Sandler reiterated its Overweight rating on Corcept with a $131 price target, citing potential growth from its hypercortisolism treatments and opportunities with relacorilant for ovarian cancer. Meanwhile, H.C. Wainwright adjusted its price target from $150 to $145, maintaining a Buy rating, and highlighted challenges with pharmacy distribution as a factor in the revenue shortfall. The firm remains optimistic about Corcept’s future, particularly with the anticipated launch of relacorilant in early 2026. Additionally, Corcept’s management has addressed previous pharmacy distribution issues, which have shown improvement since March, contributing to a record number of tablets dispensed in the following months. The company’s strategic positioning and ongoing developments in oncology and endocrinology suggest robust long-term growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.